Physician profile
Rominder Kaur
NPI 1902899396
$2,964.59
in general payments reported to CMS, 2019-2025
25 companies · $898 in 2025
The $898 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $241 · 2020: $101 · 2021: $334 · 2022: $352 · 2023: $283 · 2024: $756 · 2025: $898.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,937.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,937.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $868.76 | 2019-2025 | Jardiance |
| Novo Nordisk INC | $295.68 | 2019-2025 | Ozempic |
| Astrazeneca Pharmaceuticals LP | $237.84 | 2019-2025 | Airsupra |
| Amgen INC. | $225.71 | 2019-2025 | Repatha, Evenity, Otezla |
| Glaxosmithkline, LLC. | $150.45 | 2023-2024 | Arexvy |
| Astellas Pharma US INC | $139.82 | 2024 | Veozah |
| Inspire Medical Systems, INC. | $134.37 | 2025 | Inspire |
| Exact Sciences Corporation | $119.22 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Pfizer INC. | $109.74 | 2019-2023 | |
| Avvisto Therapeutics, LLC | $79.21 | 2024-2025 | Cycloset |
| Eisai INC. | $72.50 | 2021-2022 | |
| Si-Bone, INC. | $69.39 | 2025 | |
| Lilly USA, LLC | $60.98 | 2021-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $57.73 | 2022-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $57.23 | 2023-2024 | Cycloset |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $52.18 | 2025 | Vyepti |
| Esperion Therapeutics, INC. | $46.47 | 2021 | |
| Amarin Pharma, INC. | $37.43 | 2019 | |
| Abbvie INC. | $33.66 | 2023 | |
| Opko Pharmaceuticals, LLC | $29.36 | 2019 | |
| Smith+Nephew, INC. | $27.93 | 2022 | |
| Medtronic, INC. | $17.51 | 2023 | Intellis Adaptivestim |
| Medtronic USA, INC. | $16.45 | 2019 | |
| Allergan, INC. | $13.06 | 2019 | |
| Sanofi Pasteur INC. | $11.91 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rominder Kaur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.